Stock Ratings / Health Care / BCTX / forecast

RNAZ (47) RMTI (28) NXTC (48) CPHI (45) ⌘ Pro Terminal →

BriaCell Therapeutics Corp. (BCTX) 12-Month Stock Forecast & Price Target Cone

Q: What is BCTX's 12-month stock price target?

BriaCell Therapeutics Corp. (BCTX) carries a 12-month consensus base price target of $3.06 (-7.6% from $3.31), with a bull-case target of $13.74 and a bear-case floor of $2.39.

Q: Is BCTX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BCTX D- (Sell — SELL) with an RQD Confidence score of 41/100.

$3.31 -5.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

BriaCell Therapeutics Corp. (BCTX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $28.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCTX)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BCTX Position Size: $10,000

Shares at $3.31: 3021.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.39

$7,221

$-2,779 (-27.8%)

12M Consensus BaseTarget $3.06

$9,245

$-755 (-7.6%)

12M Bull Case BreakoutTarget $13.74

$41,511

+$31,511 (+315.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$3	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$13	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCTX)

✓Walkthrough of BCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.81%▼ SUPPORT BREAKDOWN

2026-10-30O $3.35H $3.35L $2.95C $3.31VOL 130.6K

RES: $4.64SUP: $3.65SMA50: $3.77SMA200: $3.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BCTX Butterfly Map → + Track BCTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCTX)

Health Care Rank #622 of 1016 ⚔️ RNAZ vs BCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BCTX vs. RNAZ, RMTI, NXTC, CPHI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BriaCell Therapeutics Corp. (BCTX) ranks #622 by composite RQD confidence (41/100, grade D-) and #808 by equity capitalization ($28.9M). Within this direct 5-issuer industry benchmark cohort, BCTX leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. NXTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with BCTX at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BCTX ACTIVE BriaCell Therapeutics Corp.	D-	41/100	—	—	—	-5.43%	$28.9M	Benchmark Subject
RNAZ TransCode Therapeutics Inc.	D	47/100	—	—	-35.0%	-0.57%	$29.3M	/rnaz-vs-bctx →
RMTI Rockwell Medical Inc.	E	28/100	—	16.9%	-10.6%	0.00%	$29.5M	/rmti-vs-bctx →
NXTC NextCure Inc.	D	48/100	—	—	-35.0%	+2.92%	$29.9M	/nxtc-vs-bctx →
CPHI China Pharma Holdings Inc.	D	45/100	—	-3.2%	-11.4%	+4.84%	$28.0M	/cphi-vs-bctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-07-31 • CIK 0001610820

In its most recent audited fiscal period (FY2025, filed 2025-07-31), BriaCell Therapeutics Corp. (BCTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.3M, operating cash flow of -$28.2M, and free cash flow of -$28.2M (-14.6% YoY). On the balance sheet, BCTX closed FY2025 with $33.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-07-31	$0	-$26.3M	-$28.2M	-$28.2M	$33.6M	—
FY2024 (FY)	2024-07-31	$0	-$4.8M	-$24.1M	-$24.6M	$9.4M	—
FY2023 (FY)	2023-07-31	$0	-$20.3M	-$23.7M	-$23.7M	—	—

3. BCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BriaCell Therapeutics Corp. (NASDAQ: BCTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $3.31 (-5.43% 1D, market cap $28.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, BCTX ranks #622 in composite RQD confidence.

How does BCTX compare to RNAZ and RMTI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCTX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RNAZ (TransCode Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $29.3M) and RMTI (Rockwell Medical Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -10.6%, cap $29.5M). Among the 5-stock peer group, BCTX leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BCTX?

Per BCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0001610820), BriaCell Therapeutics Corp. generated $0 in revenue, -$26.3M in net income, and -$28.2M in free cash flow against $33.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

BCTX last traded at $3.31 (-5.43% on volume of 62,901 shares), positioning the stock -12.20% below its 50-day simple moving average ($3.77) and -13.12% below its 200-day simple moving average ($3.81). Across its 52-week range of $2.60 to $13.09, BCTX sits at the 6.8% percentile with a 14-day RSI of 31.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).

BCTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BCTX's 12-month stock price target?

BriaCell Therapeutics Corp. (BCTX) carries a 12-month consensus base price target of $3.06 (-7.6% from $3.31), with a bull-case target of $13.74 and a bear-case floor of $2.39.

Is BCTX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BCTX D- (Sell — SELL) with an RQD Confidence score of 41/100.

Direct Sub-Reports: BCTX RQD Cockpit BCTX 12M Forecast BCTX Earnings & Move BCTX Dividends & DRIP BCTX Insiders & 13F BCTX Whale Options BCTX Profit Sankey BCTX News & Why